Table 1. Sample demographics.
HV | NAPD | Statistics (P-value, test statistic) | |
---|---|---|---|
Gender | (1, 0a) | ||
Male | 8 | 8 | |
Female | 4 | 4 | |
Age | 48.08 (9.94) | 44.67 (11.24) | (0.44, −0.79b) |
Educationc | 5.83 (1.4) | 5.33 (1.44) | (0.4, 0.86a) |
Smoking | (0.38, 0.54a) | ||
Nonsmoker | 11 | 10 | |
Smoker | 1 | 2 | |
Cannabis lifetimed | 0.23 (0.83) | 0.67 (1.23) | (0.31, 1.04) |
Other drugs lifetimed,e | 0 (0) | 0.01 (0.04) | (0.31, 1.04) |
Injected radioligand (MBq) | 189.83 (8.2) | 187.92 (10.86) | (0.4, −0.85b) |
Specific activity (GBq) | 2611.42 (872.96) | 2146.25 (1198.6) | (0.98, −0.03b) |
Current symptomsf | — | 11.83 (3.93) | — |
Years off AP | — | 7.09 (4.96) | — |
Cumulative haloperidol equivalentsg | — | 4303.07 (12 280.64) | — |
Abbreviations: AP, antipsychotics; HV, healthy volunteer; NAPD, non-affective psychotic disorder.
Chi2 test.
T-test.
Highest finished education, scored on a scale ranging from 1 (primary school) to 8 (Masters degree).
Lifetime use scored on a scale ranging from 1 (one to five times) to 8 (>100 times).
Stimulants, sedatives, opiates, cocaine, psychedelics, XTC, MDMA, PCP and inhalants subscales.
Positive subscale of the Positive and Negative Syndrome Subscale (PANSS).
Cumulative haloperidol equivalents were calculated by converting the weekly antipsychotics dose to haloperidol equivalents and multiplying it by the number of weeks the antipsychotics were taken.